Protara Therapeutics, Inc. (TARA) — SEC Filings
Protara Therapeutics, Inc. (TARA) — 30 SEC filings. Latest: 8-K (Dec 15, 2025). Includes 13 8-K, 6 SC 13G, 5 10-Q.
View Protara Therapeutics, Inc. on SEC EDGAR
Overview
Protara Therapeutics, Inc. (TARA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 10, 2025: Protara Therapeutics, Inc. (TARA) reported a net loss of $13.258 million for the three months ended September 30, 2025, an increase from the $11.219 million net loss in the same period of 2024. For the nine months ended September 30, 2025, the net loss widened to $40.132 million, compared to $31.827
Sentiment Summary
Across 30 filings, the sentiment breakdown is: 2 bearish, 28 neutral. The dominant filing sentiment for Protara Therapeutics, Inc. is neutral.
Filing Type Overview
Protara Therapeutics, Inc. (TARA) has filed 13 8-K, 5 10-Q, 2 DEF 14A, 2 10-K, 6 SC 13G, 2 SC 13G/A with the SEC between Feb 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (30)
Risk Profile
Risk Assessment: Of TARA's 17 recent filings, 2 were flagged as high-risk, 8 as medium-risk, and 7 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | N/A |
| Net Income | $ -40,132,000 |
| EPS | N/A |
| Debt-to-Equity | 0.09 |
| Cash Position | $ 12,551,000 |
| Operating Margin | N/A |
| Total Assets | $ 144,636,000 |
| Total Debt | $ 12,345,000 |
Key Executives
- Dr. Jonathan G. T. Feeney
Industry Context
Protara Therapeutics operates in the highly competitive and capital-intensive biotechnology sector, focusing on developing novel therapies. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory hurdles. Success often hinges on clinical trial outcomes and the ability to secure substantial funding to advance drug candidates through development and commercialization.
Top Tags
Biotechnology (3) · corporate-governance (3) · 10-Q (3) · biotech (3) · Protara Therapeutics (3) · Net Loss (2) · R&D Expenses (2) · quarterly-report (2) · sec-filing (2) · material-agreement (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss (Q3 2025) | $13.258M | Increased from $11.219M in Q3 2024, indicating widening losses. |
| Net Loss (YTD Sept 2025) | $40.132M | Increased from $31.827M in YTD Sept 2024, reflecting higher operating expenses. |
| Cash & Cash Equivalents (Sept 30, 2025) | $12.551M | Significant decrease from $162.798M at Dec 31, 2024, highlighting rapid cash burn. |
| Research & Development Expenses (YTD Sept 2025) | $29.509M | Increased from $22.205M in YTD Sept 2024, showing intensified drug development. |
| Purchase of Marketable Debt Securities (YTD Sept 2025) | $141.923M | Major investing activity contributing to the decrease in cash and cash equivalents. |
| Common Shares Outstanding (Nov 6, 2025) | 38,587,260 | Increased from 35,044,772 at Dec 31, 2024, indicating potential dilution. |
| Marketable Debt Securities (Current, Sept 30, 2025) | $120.119M | Provides liquidity, but represents a shift from cash and cash equivalents. |
| Net Cash Used in Operating Activities (YTD Sept 2025) | $39.415M | Increased from $26.500M in YTD Sept 2024, demonstrating higher operational cash outflow. |
| Net Loss | $7.5M | for the three months ended June 30, 2025, compared to $8.2M in prior year |
| Research and Development Expenses | $5.1M | for the three months ended June 30, 2025, driven by TARA-002 clinical trials |
| General and Administrative Expenses | $2.4M | for the three months ended June 30, 2025 |
| Cash and Cash Equivalents | $25.3M | as of June 30, 2025, providing liquidity |
| Revenue | 0 | for the three months ended June 30, 2025, indicating pre-commercial stage |
| Annual Meeting Date | 20250611 | Shareholders will vote on proposals at this date. |
| Filing Date | 20250425 | The proxy statement was filed on this date. |
Frequently Asked Questions
What are the latest SEC filings for Protara Therapeutics, Inc. (TARA)?
Protara Therapeutics, Inc. has 30 recent SEC filings from Feb 2024 to Dec 2025, including 13 8-K, 6 SC 13G, 5 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of TARA filings?
Across 30 filings, the sentiment breakdown is: 2 bearish, 28 neutral. The dominant sentiment is neutral.
Where can I find Protara Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Protara Therapeutics, Inc. (TARA) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Protara Therapeutics, Inc.?
Key financial highlights from Protara Therapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for TARA?
The investment thesis for TARA includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Protara Therapeutics, Inc.?
Key executives identified across Protara Therapeutics, Inc.'s filings include Dr. Jonathan G. T. Feeney.
What are the main risk factors for Protara Therapeutics, Inc. stock?
Of TARA's 17 assessed filings, 2 were flagged high-risk, 8 medium-risk, and 7 low-risk.
What are recent predictions and forward guidance from Protara Therapeutics, Inc.?
Forward guidance and predictions for Protara Therapeutics, Inc. are extracted from SEC filings as they are enriched.